Compare
Jasper Therapeutics, Inc. vs Champions Oncology, Inc. vs Pluri Inc. vs Outlook Therapeutics, Inc.
| Latest fiscal year | Jasper Therapeutics, Inc. JSPR | Champions Oncology, Inc. CSBR | Pluri Inc. PLUR | Outlook Therapeutics, Inc. OTLK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-04-30 | 2026-06-30 | 2025-09-30 |
| Revenue | n/a | $59.42M | $1.02M | $1.41M |
| Revenue growth (YoY) | n/a | +4.4% | -24.0% | n/a |
| Gross margin | n/a | 48.0% (computed) | 44.6% | 4.0% |
| Operating margin | n/a | -1.9% | n/m | n/m |
| Net margin | n/a | -2.0% | n/m | n/m |
| Net income | -$75.80M | -$1.18M | -$23.82M | -$62.42M |
| EPS (Diluted) | -$3.95 | -$0.08 | -$2.44 | -$1.79 |
| Operating cash flow | -$77.16M | -$4.47M | -$19.59M | -$51.83M |
| Free cash flow | n/a | -$5.04M | -$20.22M | n/a |
| Cash & equivalents | $28.69M | n/a | $3.53M | $8.08M |
| Total assets | $35.78M | $26.99M | $24.88M | $18.58M |
| Total liabilities | $31.63M | $22.92M | n/a | $50.77M |
| Shareholders' equity | $4.15M | $3.94M | -$23.04M | -$32.19M |
| Return on year-end equity | n/m | -29.8% | n/a | n/a |
| Shares outstanding | 28.00M | 13.89M | 10.82M | 53.89M |
Revenue, most recent five fiscal years
| Fiscal year | Jasper Therapeutics, Inc. | Champions Oncology, Inc. | Pluri Inc. | Outlook Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $59.42M Ended 2026-04-30 | $1.02M Ended 2026-06-30 | $1.41M Ended 2025-09-30 |
| 1 year earlier | n/a | $56.94M Ended 2025-04-30 | $1.34M Ended 2025-06-30 | n/a |
| 2 years earlier | n/a | $50.16M Ended 2024-04-30 | $326.0K Ended 2024-06-30 | n/a |
| 3 years earlier | n/a | $53.87M Ended 2023-04-30 | $287.0K Ended 2023-06-30 | n/a |
| 4 years earlier | n/a | $49.11M Ended 2022-04-30 | $234.0K Ended 2022-06-30 | n/a |